If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca, global, science-led biopharmaceutical company, announced that its Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: “FASENRA is already well established for the treatment of severe eosinophilic asthma, and with this ...

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...